
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid Ltd, with a market capitalization of approximately $74 million, is positioned favorably as it approaches a pivotal regulatory milestone for its product candidate D-PLEX100, aimed at preventing surgical site infections. Notably, the favorable feedback received from the FDA during pre-New Drug Application interactions bolsters the outlook for a rolling submission anticipated in early 2026, which, combined with successful regulatory inspections, enhances investor confidence regarding D-PLEX100's potential approval. Furthermore, PolyPid's recent improvements in regulatory clarity, the advancement of its drug delivery platform, and strategic collaborations, such as with AdvanzPharma in the EU, contribute to a positive sentiment among investors as the company transitions towards a commercialization phase.
Bears say
PolyPid Ltd faces substantial risks that contribute to a negative outlook on its stock, primarily due to the potential failure of its clinical candidates to achieve statistically significant results, which could considerably diminish the value of its product portfolio. Additionally, even successful clinical outcomes do not guarantee regulatory approval, which remains a critical hurdle for the company's growth prospects, with vital market entry delays anticipated for key products like D-PLEX100. Compounding these challenges, the company is also exposed to complexities in patent procedures and potential revenue erosion starting in 2036, alongside elevated R&D expenses that exceed consensus expectations, signaling a lack of financial efficiency.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares